Archives
Press Releases
advertisement
June 8, 2022
- Success of Omnipod 5 closed-loop system in preschoolers continues at 1 year
- Ultra-rapid lispro noninferior to standard version in children
- Medtronic expects diabetes unit’s struggles to continue as rivals grow sales, launch products
- Pivotal Trial Results of the iLet® Bionic Pancreas to Be Presented at the ADA’s 82nd Scientific Sessions
- Abbott Announces Development of Novel Continuous Glucose-Ketone Monitoring System
- New Study Shows Open-Source Automated Insulin Delivery is a Safe and Effective Treatment Option for People with Type 1 Diabetes
- Dexcom CEO expects ‘science boom’ with CGM, automated insulin delivery
- Insulet’s Omnipod 5 “significantly improves” glycemic outcomes in very young children
- Risk of Severe Diabetes Ketoacidosis Spiked Among Pediatric Type 1 Diabetes Patients During the Pandemic
- Beyond Type 1 and Life for a Child Illuminate the State of Type 1 Diabetes in Rwanda
- American Diabetes Association Symposium to Bring to Light the Impact of Suicide and Depression on Adolescents with Type 1 Diabetes
- T1D Exchange to Highlight New Real-World Findings Across 18 Presentations at the American Diabetes Association 82nd Scientific Sessions
May 18, 2022
- Breakthrough in Type 1 Diabetes Got iLet Bionic Pancreas System
- NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes
- FDA approves Lilly diabetes drug that analysts expect to be a big seller
- MannKind Corporation Announces Agreement to Acquire V-Go® Insulin Delivery Device From Zealand Pharma
May 4, 2022
- Abbott, Camdiab and Ypsomed Unveil New Automated Insulin Delivery Partnership for People with Diabetes
- New Analysis Shows that Abbott’s Freestyle Libre System Provides Similar and Sustained Reductions in Glucose Levels For People with Both Type 1 and Type 2 Diabetes
- Dexcom study shows strong accuracy for next-gen G7 CGM in pediatric T1D patients
- The iLet® Bionic Pancreas Significantly Reduced HbA1c and Improved Time in Range vs Standard of Care for a Diverse Range of People with Type 1 Diabetes
- Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
- Walmart launches virtual diabetes care program
April 20, 2022
- Introducing a New Standard for Diabetes Care
- Mylan Pharmaceuticals Inc., a Viatris Company, Conducting Voluntary Nationwide Recall of One Batch of Insulin Glargine (Insulin glargine-yfgn) Injection, 100 units/mL (U-100), Due to the Potential for a Missing Label in the Batch
- The mysterious case of Viatris and the missing insulin label deepens
- Dexcom announces availability of G6 for Tricare members as formulary pharmacy benefit
- Surf’s up: Startup stoked as Chris Garabedian fund funnels cash into ultra-rapid insulin program
advertisement
